Literature DB >> 26081063

Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfected patient on long-term maintenance methadone therapy.

Cristina Gervasoni1, Anna Maria Peri, Dario Cattaneo, Sara Baldelli, Giuliano Rizzardini, Laura Milazzo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26081063     DOI： 10.1007/s00228-015-1890-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  9 in total

1.  Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.

Authors:  Surakit Pungpapong; Bashar Aqel; Michael Leise; K Tuesday Werner; Jennifer L Murphy; Tanisha M Henry; Kristen Ryland; Amy E Chervenak; Kymberly D Watt; Hugo E Vargas; Andrew P Keaveny
Journal:  Hepatology       Date:  2015-04-27       Impact factor: 17.425

Review 2.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  New hepatitis C therapies: the toolbox, strategies, and challenges.

Authors:  Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2014-03-12       Impact factor: 22.682

4.  The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.

Authors:  Brian L Pearlman; Carole Ehleben; Michael Perrys
Journal:  Gastroenterology       Date:  2014-12-31       Impact factor: 22.682

5.  Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.

Authors:  Christophe Moreno; Christophe Hezode; Patrick Marcellin; Stefan Bourgeois; Sven Francque; Didier Samuel; Fabien Zoulim; Jean-Didier Grange; Umesh Shukla; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Bart Fevery; Monika Peeters; Maria Beumont; Wolfgang Jessner
Journal:  J Hepatol       Date:  2015-01-14       Impact factor: 25.083

Review 6.  Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.

Authors:  Lindsey M Childs-Kean; Elizabeth O Hand
Journal:  Clin Ther       Date:  2015-01-16       Impact factor: 3.393

7.  Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.

Authors:  Jun-Sheng Wang; C Lindsay DeVane
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

8.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

Review 9.  Hepatitis C in HIV-infected patients: impact of direct-acting antivirals.

Authors:  Kian Bichoupan; Douglas T Dieterich
Journal:  Drugs       Date:  2014-06       Impact factor: 11.431
  9 in total
  1 in total

1.  Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.

Authors:  Karine Lacombe; Hélène Fontaine; Catherine Dhiver; Sophie Metivier; Eric Rosenthal; Teresa Antonini; Marc Antoine Valantin; Patrick Miailhes; Stanislas Harent; Dominique Batisse; Georges-Philippe Pageaux; Julie Chas; Hugues Aumaitre; Stephanie Dominguez; Thierry Allegre; Alain Lafeuillade; Eric Billaud; Pierre De Truchis; Philippe Perre; Vincent Leroy; Victor De Ledinghen; Philippe Sogni; François Dabis; Yue Zhao; Anne Filipovics; Larysa Fedchuk; Raoudha Akremi; Yacia Bennai; Dominique Salmon Ceron
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.